Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of L-fucose in medicines and health-care products for treating gastrointestinal lesions

A technology for health care products and digestive tract, which is applied in the application field of L-fucose in medicines and health care products for digestive tract lesions, can solve problems such as high side effects and low efficacy, reduce inflammation damage and diarrhea, and reduce clinical adverse effects. the effect of the event

Inactive Publication Date: 2017-05-17
XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to provide an application of L-fucose in medicines for gastrointestinal lesions, which solves the defects of high side effects and low efficacy of existing treatments in improving the long-term prognosis of gastrointestinal lesions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of L-fucose in medicines and health-care products for treating gastrointestinal lesions
  • Application of L-fucose in medicines and health-care products for treating gastrointestinal lesions
  • Application of L-fucose in medicines and health-care products for treating gastrointestinal lesions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1 Establishment of DSS-induced enteritis model and intervention grouping

[0045] 1. Subjects

[0046] 150 CD57 male mice aged 6-8 weeks, weighing 20-22g, were purchased from the Hubei Provincial Center for Disease Control and Prevention. According to the "Guidelines for the Care and Use of Experimental Animals" issued by the National Academy of Sciences in 2011, the animals were raised at Huazhong University of Science and Technology Animal experiment center SPF level experimental animal room;

[0047] 2. Model grouping

[0048] Control group: 10 rats were given normal saline orally without any treatment.

[0049] Fucose-only intervention group: 10 rats were given intragastric administration of L-fucose alone.

[0050] DSS model group: modeled according to the standard of DSS-induced enteritis model, administrated with normal saline, a total of 20 rats.

[0051] DSS model fucose intervention group: the model was established according to the standard of DSS-in...

Embodiment 2

[0056] Example 2 Effect of L-fucose on body weight of mice

[0057] 1. Materials: L-fucose was purchased from Sigma-Aldrich, USA, and dissolved in PBS isotonic buffer before gavage

[0058] Animals and grouping: CD57 male mice aged 6-8 weeks were divided into control group;

[0059] DSS model group; DSS model L-fucose intervention group three groups

[0060] 2. Reagents and instruments: small animal gavage equipment (Shanghai Medical Instrument Factory, China)

[0061] 3. Method:

[0062] 1) DSS-induced acute enteritis model: record the changes in DAI and body weight of the mice in each group every day for 7 days after modeling, and make statistics and draw the curves of DAI scores and body weight changes

[0063] 2) DSS-induced chronic enteritis model: record the body weight changes of mice in each group every day until the completion of 3 rounds, and make statistics and draw the body weight change curve

[0064] 4. Results: if figure 1 As shown, for the chronic DSS-indu...

Embodiment 3

[0065] Example 3 Effect of L-fucose on the immune system

[0066] 1. Materials: L-fucose was purchased from Sigma-Aldrich, USA, and dissolved in PBS isotonic buffer before gavage

[0067] 2. Animals and grouping: CD57 male mice aged 6-8 weeks were divided into three groups: control group; DSS model group; DSS model fucose intervention group

[0068] 3. Reagents and instruments: PBS, Percoll separation solution, trypan blue, anti-CD103, CD11b antibodies, etc.; Rongsheng refrigerator BCD-575WYM (Rongsheng Company, China), Thermo Forma-86°C refrigerator (Thermo Company, USA), low temperature, High-speed centrifuge (Eppendorf, Germany)

[0069] 4. Method:

[0070] (1) Mice were killed by breaking the vertebrae, soaked in 75% alcohol for 3 minutes, and all small intestine samples were taken, rinsed thoroughly in sterilized PBS solution.

[0071] (2) Cut into pieces of about 0.5cm, put them into 40ml of sterile PBS solution containing 1mmol / L DTT, 1mmol / L EDTA, 1% antibiotics (Pe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of L-fucose in medicines and health-care products for treating gastrointestinal lesions. The L-fucose is used for treating the gastrointestinal lesions, such as inflammatory bowel disease, functional gastrointestinal disorder and irritable bowel syndrome. The medicine is a carbohydrate medicine, since the adverse effect is less, and the tolerance of a patient is good, so that the medicine can be widely applied into clinic. The medicine has the advantages that the L-fucose is used in an early period of the gastrointestinal lesions, the activation of mesenteric lymph node Treg cells is regulated by DC cells, the differentiation potential of colons Th1 and Th17 is inhibited, the generation of bile acid is inhibited by regulating the intestinal flora, the function of inhibiting the contraction and spasm of intestinal muscles is realized by an nNOS path, the intestinal inflammation and weight-losing conditions are improved, and the patient can obtain an obvious long-term prognosis benefit; because of limitations of related existing therapy medicines, namely multiple medicine types, large side effect and poor compliance, a new therapy strategy for treating the patients with the gastrointestinal lesions, such as the inflammatory bowel disease, the functional gastrointestinal disorder and the irritable bowel syndrome, is provided.

Description

technical field [0001] The invention relates to the field of treating gastrointestinal lesions, and specifically refers to the application of L-fucose in medicines and health products for gastrointestinal lesions. Background technique [0002] Gastrointestinal lesions (disease code: K92.902, pinyin code: XHDBB) are an important part of the spectrum of human diseases, including functional gastrointestinal diseases, inflammatory bowel diseases and other diseases, because of their high incidence and Serious damage to the quality of life has become a serious problem that threatens human health in various countries for a long time. Among them, changes in intestinal function, increased inflammation, and weight loss caused by gastrointestinal lesions are the main reasons for the decline in the quality of life of many patients and even disability and death. A large number of studies have found that changes in intestinal function, increased inflammation, and weight loss after gastro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7004A61P1/00A23L33/125
CPCA23V2002/00A61K31/7004A23V2200/32
Inventor 侯晓华蔺蓉
Owner XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com